Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders (2023)

Editorial
Written By Simon Ruffell

Grace Blest-Hopley, Ben Amit, Aisling O'Neill, & Simon Ruffell

Medical cannabis and psychedelics have shown promising results in treating various psychiatric disorders, but the lack of robust evidence remains a significant challenge. In this edition, we share intriguing insights into the specific applications of certain substances.

Simon Ruffell
Previous

Ayahuasca: A review of historical, pharmacological, and therapeutic aspects (2023)
Next

Ayahuasca (in Psychedelics as Psychiatric Medications, 2023)